Few data are currently available on the appropriate management of this infection, and no specific therapy is known, often relying on the introduction of mTOR inhibitors for HHV‐8 infection and antivirals/immunomodulatory agents for managing KICS. This evidence concerns the gene MTOR and human herpesvirus 8 infection.